Supported by:
This session evaluated how health care and frontline medicine will emerge from the COVID-19 pandemic. Being one of the sectors that was most affected by the crisis, healthcare was tackled from different points of view.
This session was composed of three conversations:
CONVERSATION 1 | Post-pandemic changes to healthcare and social welfare systems
16:00 – 18:00 CET
Speakers discussed how social welfare and health systems will be altered in the Post-COVID Era, as both a consequence and a response to the pandemic.
Speakers:
Ben Osborn, Regional President Hospital for International Developed Markets, Pfizer Hospital Business
Angela Spatharou, Senior Partner and EMEA Industry Leader, Healthcare & Life Sciences, IBM Consulting
Agnès Soucat, Director for Health Systems Governance and Financing, World Health Organization
Chris Wolff, Deputy Director, Global Delivery Program, Global Development Division, Bill and Melinda Gates Foundation
Moderated by Vikram Patel, Pershing Square Professor of Global Health and Wellcome Trust Principal Research Fellow, Harvard Medical School
CONVERSATION 2 | Risk assessment and prevention
16:00 – 18:00 CET
Medical risk assessment was examined, particularly with a focus on how the spread of infectious diseases can be predicted and halted. Can we conceive and design a physical environment that is better suited to disease prevention?
Speakers:
Pol Vandenbroucke, Chief Medical Officer, Pfizer’s Hospital Business Unite
Andrew J. Tatem, Director of WorldPop, University of Southampton
Jeffrey Shaman, Professor, Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University
John P.A. Ioannidis, C.F. Rehnborg Chair in Disease Prevention, Stanford University
Robert C. Gallo, The Homer & Martha Gudelsky Distinguished Professor in Medicine, University of Maryland School of Medicine; Co-Founder & Director, Institute of Human Virology
Tolullah Oni, Clinical Senior Research Associate, MRC Epidemiology Unit; Honorary Associate Professor, University of Cambridge
Wolfgang Philipp, Head of Unit, Public Health, Country Knowledge, Crisis Management Directorate of the European Commission
Moderated by Christopher Dye, Professor of Epidemiology, University of Oxford
CONVERSATION 3 | Technological breakthroughs driving medical advances
16:00 – 18:00 CET
This conversation navigated the technological breakthroughs that are driving medical advances, with participants discussing their vision for the future of healthcare and medicine.
Speakers:
Edward Abrahams, President, Personalized Medicine Coalition
Jennifer Miller, Founder, Bioethics International
Kenji Shibuya, Professor and Director of the Institute of Population Health, King’s College London
Laurie H. Glimcher, President and CEO, Dana-Farber Cancer Institute; Richard and Susan Smith Professor of Medicine, Harvard Medical School
Othman Laraki, Co-founder and CEO, Color
Peer M. Schatz, Managing Director, PS-Capital Management GmbH
Yoshiyuki Sankai, CEO and President, CYBERDYNE Inc.
Moderated by Carlos Bustamante, Principal Investigator, Stanford University School of Medicine